Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

被引：0
|
作者：
Philip Q. Bao
Ramesh K. Ramanathan
Alyssa Krasinkas
Nathan Bahary
Barry C. Lembersky
David L. Bartlett
Steven J. Hughes
Kenneth K. Lee
A. James Moser
Herbert J. Zeh
机构：
[1] Stony Brook University Hospital,Department of Surgery
[2] Virginia G. Piper Cancer Center,Department of Pathology
[3] University of Pittsburgh Medical Center,Department of Medical Oncology
[4] University of Pittsburgh Medical Center,Department of Surgery, Division of Surgical Oncology
[5] University of Pittsburgh Medical Center,undefined
来源：
Annals of Surgical Oncology | 2011年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 323
相关论文
共 50 条
  • [41] Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial
    Abrams, Ross A.
    Winter, Kathryn A.
    Safran, Howard
    Goodman, Karyn A.
    Regine, William F.
    Berger, Adam C.
    Gillin, Michael T.
    Philip, Philip A.
    Lowy, Andrew M.
    Wu, Abraham
    DiPetrillo, Thomas A.
    Corn, Benjamin W.
    Seaward, Samantha A.
    Haddock, Michael G.
    Song, Suisui
    Jiang, Yixing
    Fisher, Barbara J.
    Katz, Alan W.
    Mehta, Sharmila
    Willett, Christopher G.
    Crane, Christopher H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (03): : 173 - 179
  • [42] Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer Phase I Study
    Ueno, Makoto
    Morinaga, Soichiro
    Hashimoto, Yusuke
    Umemoto, Kumiko
    Sasahira, Naoki
    Saiura, Akio
    Seyama, Yasuji
    Honda, Goro
    Ioka, Tatsuya
    Takahashi, Hidenori
    Miyamoto, Atsushi
    Nakamori, Shoji
    Unno, Michiaki
    Takadate, Tatsuyuki
    Mizuno, Nobumasa
    Shimizu, Yasuhiro
    Ueno, Hideki
    Sugiyama, Masanori
    Fukutomi, Akira
    Shimizu, Satoshi
    Okusaka, Takuji
    Furuse, Junji
    PANCREAS, 2021, 50 (01) : 83 - 88
  • [43] Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
    Han, Boram
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Kim, Jung Hoon
    Kim, Ho Young
    Song, Hunho
    Park, Choong Kee
    Moon, Sung Hoon
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Lee, Jung Woo
    Zang, Dae Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer
    Ma, Wen Wee
    Herman, Joseph M.
    Jimeno, Antonio
    Laheru, Daniel
    Messersmith, Wells A.
    Wolfgang, Christopher L.
    Cameron, John L.
    Pawlik, Timothy M.
    Donehower, Ross C.
    Rudek, Michelle A.
    Hidalgo, Manuel
    TRANSLATIONAL ONCOLOGY, 2010, 3 (06): : 373 - 379
  • [45] Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005
    Wisniewski, Mathilde
    Placide, Pierre-Alain
    Granier, Sandra
    Al Shatti, Yacoub
    Al Qalaf, Shuaib
    Bouattour, Mohamed
    Lamuraglia, Michele
    Hammel, Pascal
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (05) : 399 - 402
  • [46] Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer
    Epelbaum, R
    Rosenblatt, E
    Nasrallah, S
    Faraggi, D
    Gaitini, D
    Mizrahi, S
    Kuten, A
    JOURNAL OF SURGICAL ONCOLOGY, 2002, 81 (03) : 138 - 143
  • [47] Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer
    Aoki, Taku
    Viatsushita, Hirokazu
    Hoshikawa, Mayumi
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    Kakimi, Kazuhiro
    CYTOTHERAPY, 2017, 19 (04) : 473 - 485
  • [48] Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Miccio, Joseph A.
    Iovoli, Austin J.
    Hermann, Gregory M.
    Singh, Anurag K.
    JAMA NETWORK OPEN, 2019, 2 (08)
  • [49] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    Van Cutsem, E.
    Li, C-P
    Nowara, E.
    Aprile, G.
    Moore, M.
    Federowicz, I.
    Van Laethem, J-L
    Hsu, C.
    Tham, C. K.
    Stemmer, S. M.
    Lipp, R.
    Zeaiter, A.
    Fittipaldo, A.
    Csutor, Z.
    Klughammer, B.
    Meng, X.
    Ciuleanu, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2067 - 2075
  • [50] Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer
    Epelbaum, R.
    Vizel, B.
    Bar-Sela, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345